Thank you for Subscribing to Life Science Review Weekly Brief
×
Life Science Review Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review
Clinical Software Solutions Architecture for CROs and Pharma Companies
Life Sciences Review | Wednesday, November 24, 2021
Leaders in the life sciences business predict a gradual transition to single platform architecture, driving the industry to adopt eClinical software solutions.
Fremont, CA: Due to the COVID-19 pandemic, the industry is moving toward eClinical software solutions that are on unified platforms. Massive volumes of data collection from an increasing number and diverse set of data sources, as well as the need for sponsors and CROs to gain more complete views of trials and act on data quickly, are driving the industry toward eClinical software solutions that are on unified platforms. Organizations that have made the switch to an external eClinical solution provider's platform have looked for ways to justify the move.
The architecture of eClinical software systems for CROs is likely to take one of two forms:
Preferred tech:
These are often huge CROs that sell both their outsourced services and their own technologies in the market. Internal development, acquisitions, or exclusive vendor partnerships may have resulted in the development of these technologies. Although these CROs prefer to utilize and sell their own technology, they also use and sell those of others.
Agnostic:
Although these CROs do not have huge internal infrastructures, they are usually capable of managing data linkages. These businesses may have a favorite eClinical solutions provider, but they will usually follow the client's wishes.
Pharmaceutical/biotech firms' eClinical software solutions architecture is likely to take one of two forms:
Large legacy companies:
Platform architectures are frequently designed wholly or primarily in-house, with a mix of cloud-hosted and in-house integration. These complicated systems come at a premium price, and new application deployments frequently necessitate a rethinking of the existing architecture.
New companies:
A triggering event (such as a merger and acquisition or a new enterprise) frequently prompts the consideration of a new or modified design. In this environment, few companies will invest in internal IT development; instead, they will explore outsourcing their studies to CROs or purchasing an eClinical platform that meets all or most of their requirements. End-to-end coverage and easy interaction with other required capabilities are essential aspects in SaaS systems.
Pharmaceutical companies will continue to evolve and adapt to their increasingly digital environment, moving away from single, fragmented point solutions and toward unified platforms. Embracing unified platforms reduces the burden on clinical development teams, allows sponsors to centralize their data to gain valuable insights across trials instead of dealing with disparate datasets isolated across several point solutions, and allows sponsors to scale to support large numbers of studies.
